Blood-based Biomarkers for Diagnosis of Alzheimer's
Recruiting
N/A
Interventional Study
Dementia Alzheimers
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 40 – 100
- Sex
- Any
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 300 (estimated)
- Sponsor
- Helse Stavanger HF · Government
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Alzheimer's disease (AD) may currently be diagnosed using molecular biomarkers in cerebrospinal fluid (CSF) and/or positron emission tomography (PET). These diagnostic procedures are highly accurate, but the high cost and low availability hamper their feasibility. Recently, ultrasensitive blood tests predicting Alzheimer pathologies in the brain have been developed. These tests have a reliable abi…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Participants suspected by their GP to have possible dementia, based on history, clinical examination and/or cognitive screening
Exclusion Criteria:
* Lack of capacity for consent as judged by the GP.
* Severe psychiatric disease, use of medication or physical disease that ac…
Contacts